Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. (PHAT) Stock Overview

Explore Phathom Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PHAT●NASDAQ
HealthcareBiotechnology
$11.95
$0.51(4.46%)
U.S. Market opens in 15h 20m

Phathom Pharmaceuticals, Inc. (PHAT)

Meyka AI Score

Z

Key Financials

Market Cap953.1M
P/E Ratio-5.62
EPS (TTM)$-1.47
ROE0.39%
Fundamental Analysis

AI Price Forecasts

1 Month$14.25
3 Months$20.61
1 Year Target$13.52

PHAT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Phathom Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PHAT on the NASDAQ shows an RSI of 58.56, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $13.52 for the NASDAQ listing.

Key metrics behind Phathom Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.62 and a market capitalization of 953.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of PHAT on the NASDAQ.

Price Performance (NASDAQ: PHAT)

1-Day Change
4.46%
5-Day Change
7.08%
1-Month Change
11.47%
3-Month Change
3.11%
6-Month Change
-16.02%
Year-to-Date (YTD) Change
-27.97%
1-Year Change
35.80%
3-Year Change
-15.07%
5-Year Change
-61.06%
All-Time (Max) Change
-51.42%

Contact Information

https://www.phathompharma.com
877 742 8466
100 Campus Drive, Florham Park, NJ, 07932

Company Facts

3,710 Employees
IPO DateOct 25, 2019
CountryUS
Actively Trading

Frequently Asked Questions